Urgent need for cost-efficient COVID-19 tests
The Indian Council of Medical Research (ICMR) has evaluated DiaCarta Inc’s QuantiVirus™ SARS-CoV-2 RT-PCR test kit for sale in India.
The evaluation showed 100% sensitivity and 100% specificity without any interference with other respiratory viruses and has been cleared for sale in the Indian market, DiaCarta said on 15 July 2020 from Richmond, California.
DiaCarta said the QuantiVirus™ SARS-CoV-2 test has been approved for distribution in Mexico.
“With an urgent global need for the availability of highly sensitive and specific tests to minimize the risk of false-negative results and mitigate the ongoing transmission of the deadly virus, we are pleased that our test has met the stringent requirements of the regulatory agencies in Mexico and India and has received regulatory approvals,” said Dr. Ramanathan Vairavan, Senior Vice President at DiaCarta.
He further said that “with the increasing incidence of COVID-19 around the globe, there is a need for cost-efficient tests that are easy to perform on commonly available qPCR platforms.
“At DiaCarta, we are committed to working with governmental and private institutions to increase test availability and arrest the spread of the coronavirus.
“In addition, the DiaCarta CLIA certified laboratory in the San Francisco Bay Area has been actively engaged to provide COVID-19 testing to support America’s ‘Back to Work’ and ‘Back to School’ initiatives,” said Vairavan.
DiaCarta is a molecular diagnostics company that has developed innovative technologies that transforms patient care by providing effective precision diagnostics using a liquid biopsy.
It’s novel XNA technology provides a high level of sensitivity as it binds to the wild-type sequence and enables only the mutant target sequence to get amplified.
Using this technology, the company has developed its highly sensitive ColoScape™ early detection Colorectal Cancer test using blood. Powered by its SuperbDNA™ technology that provides a high level of detection as it amplifies the signal and requires no RNA/DNA extraction or amplification, the company has developed its revolutionary RadTox™ test that personalizes radiation therapy, mitigates adverse events and enhances patient care.
Based in Richmond, California the company is ISO certified, GMP-compliant and offers CLIA certified laboratory services to its customers. #coronavirus #COVID-19 #health #respiratory #virus #drugs #vaccine /fiinews.com
